{"id":24226,"date":"2022-12-20T07:08:35","date_gmt":"2022-12-20T07:08:35","guid":{"rendered":"https:\/\/rhepa.se\/?p=24226"},"modified":"2022-12-20T07:08:54","modified_gmt":"2022-12-20T07:08:54","slug":"rhenman-partners-forstarker-sitt-investeringsteam-med-biopharmananlytiker","status":"publish","type":"post","link":"https:\/\/rhepa.se\/en\/rhenman-partners-forstarker-sitt-investeringsteam-med-biopharmananlytiker\/","title":{"rendered":"Rhenman &#038; Partners f\u00f6rst\u00e4rker sitt investeringsteam med biopharmananlytiker"},"content":{"rendered":"<p>Rhenman &amp; Partners anst\u00e4ller Amennai Beyeen som analytiker inom biopharma d\u00e4r han kommer att ha ett s\u00e4rskilt fokus p\u00e5 bolag inom l\u00e4kemedelsutveckling. Amennai ansluter till Rhenman &amp; Partners investeringsteam p\u00e5 fem personer, alla baserade i Stockholm. Amennai kommer n\u00e4rmast fr\u00e5n Novartis d\u00e4r han jobbat med utvecklingsprocesser och lansering av l\u00e4kemedel. Amennai har tidigare doktorerat inom neuroimmunologi vid Karolinska Institutet.<\/p>\n<p>\u201dVi \u00e4r v\u00e4ldigt glada att h\u00e4lsa Amennai v\u00e4lkommen till Rhenman &amp; Partners. Amennais gedigna bakgrund och kompetens inom forskning och hans erfarenheter fr\u00e5n l\u00e4kemedelsbolag d\u00e4r han n\u00e4ra kunnat f\u00f6lja processer fr\u00e5n id\u00e9 till f\u00e4rdig produkt g\u00f6r honom till ett mycket bra tillskott till v\u00e5rt investeringsteam.\u201d \u2013 s\u00e4ger Henrik Rhenman, medgrundare och investeringschef p\u00e5 Rhenman &amp; Partners.<\/p>\n<p>&#8221;Det k\u00e4nns v\u00e4ldigt gl\u00e4djande att f\u00e5 b\u00f6rja p\u00e5 Rhenman &amp; Partners. Jag \u00e4r oerh\u00f6rt imponerad av teamets gedigna kunskaper inom h\u00e4lso- och sjukv\u00e5rdssektorn samt fondens m\u00e5ngsidiga investeringsprocess, vilket \u00e5terspeglas i goda resultat genom \u00e5ren. Jag ser fram emot att f\u00e5 ansluta till detta kompetenta team och bidra med mina erfarenheter fr\u00e5n life science-sektorn.&#8221; \u2013 s\u00e4ger Amennai Beyeen<\/p>\n<p><img fetchpriority=\"high\" decoding=\"async\" class=\"alignnone size-medium wp-image-24227\" src=\"https:\/\/rhepa.se\/wp-content\/uploads\/2022\/12\/Ame_landscape-300x225.jpg\" alt=\"\" width=\"300\" height=\"225\" srcset=\"https:\/\/rhepa.se\/wp-content\/uploads\/2022\/12\/Ame_landscape-300x225.jpg 300w, https:\/\/rhepa.se\/wp-content\/uploads\/2022\/12\/Ame_landscape-1024x768.jpg 1024w, https:\/\/rhepa.se\/wp-content\/uploads\/2022\/12\/Ame_landscape-768x576.jpg 768w, https:\/\/rhepa.se\/wp-content\/uploads\/2022\/12\/Ame_landscape-1536x1152.jpg 1536w, https:\/\/rhepa.se\/wp-content\/uploads\/2022\/12\/Ame_landscape-2048x1536.jpg 2048w, https:\/\/rhepa.se\/wp-content\/uploads\/2022\/12\/Ame_landscape-787x590.jpg 787w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>Amennai tilltr\u00e4der sin roll p\u00e5 Rhenman &amp; Partners i april.<\/p>","protected":false},"excerpt":{"rendered":"<p>Rhenman &amp; Partners anst\u00e4ller Amennai Beyeen som analytiker inom biopharma d\u00e4r han kommer att ha ett s\u00e4rskilt fokus p\u00e5 bolag inom l\u00e4kemedelsutveckling. Amennai ansluter till Rhenman &amp; Partners investeringsteam p\u00e5 fem personer, alla baserade i Stockholm. Amennai kommer n\u00e4rmast fr\u00e5n Novartis d\u00e4r han jobbat med utvecklingsprocesser och lansering av l\u00e4kemedel. Amennai har tidigare doktorerat inom [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-24226","post","type-post","status-publish","format-standard","hentry","category-okategoriserad"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/posts\/24226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/comments?post=24226"}],"version-history":[{"count":2,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/posts\/24226\/revisions"}],"predecessor-version":[{"id":24230,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/posts\/24226\/revisions\/24230"}],"wp:attachment":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/media?parent=24226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/categories?post=24226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/tags?post=24226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}